KYVERNA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | +5.09% |
|
+12.60% | 0.00% |
| Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
| Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Kyverna Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
6f5fe542ecd24cd4ac72.k6vPG65Gv4CDlgrfM1SZLmipNn6ILXDQxHp27AATgDw.wPniassf5bfo9WSUCyXzSDzFBDjnGhqgki0ApEMl6FHQkr1r6jbu-vrMSw~390b059ceb7520bfcb62d03e0e0e4030
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.63
USD
Average target price
42.75
USD
Spread / Average Target
+192.21%
High Price Target
48
USD
Spread / Highest target
+228.09%
Low Price Target
39
USD
Spread / Lowest Target
+166.58%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Kyverna Therapeutics, Inc.
| Morgan Stanley | |
| JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- KYTX Stock
- Consensus Kyverna Therapeutics, Inc.
